View Item 

Panton–Valentine leukocidin-positive Staphylococcus aureus: a position statement from the International Society of Chemotherapy

Access Status
Fulltext not available
Authors
Saeed, K.
Gould, I.
Espositio, S.
Ahmad-Saeed, N.
Ahmed, S.
Alp, E.
Bal, A.
Bassetti, M.
Bonnet, E.
Chan, M.
Coombs, Geoffrey
Dancer, S.
David, M.
De Simone, G.
Dryden, M.
Guardabassi, L.
Hanitsch, L.
Hijazi, K.
Krüger, R.
Lee, A.
Leistner, R.
Pagliano, P.
Righi, E.
Schneider-Burrus, S.
Skov, R.
Tattevin, P.
Van Wamel, W.
Vos, M.
Voss, A.
Date
2018
Type
Journal Article

Metadata
Show full item record
Citation
Saeed, K. and Gould, I. and Espositio, S. and Ahmad-Saeed, N. and Ahmed, S. and Alp, E. and Bal, A. et al. 2018. Panton–Valentine leukocidin-positive Staphylococcus aureus: a position statement from the International Society of Chemotherapy. International Journal of Antimicrobial Agents. 51 (1): pp. 16-25.
Source Title
International Journal of Antimicrobial Agents
DOI
ISSN
School
School of Pharmacy and Biomedical Sciences
URI
Collection
Abstract

Panton–Valentine leukocidin (PVL), a pore-forming cytotoxic secreted toxin, has been associated with severe Staphylococcus aureus pneumonia and prototypical skin lesions. The reported incidence and prevalence of PVL-positive S. aureus (PVLP-SA) varies globally and suffers from a selective reporting bias towards community-associated methicillin-resistant S. aureus (CA-MRSA). Recent studies, however, have identified PVL-positive methicillin-susceptible S. aureus (MSSA) more frequently than previously expected. In this review, a group of experts from four continents affiliated with the International Society of Chemotherapy (ISC) offer a position statement on the important aspects of PVL in S. aureus epidemiology, antimicrobial treatment and decolonisation, and aim to highlight future areas for collaboration and research.